Shang J.,Hangmen Wuyi Traditional Chinese Medicine Hospital |
Deng L.,Hangmen Wuyi Traditional Chinese Medicine Hospital |
Gao W.,Hangmen Wuyi Traditional Chinese Medicine Hospital |
Ding K.,Hangmen Wuyi Traditional Chinese Medicine Hospital |
And 5 more authors.
Cancer Research and Clinic | Year: 2014
Objective: To evaluate the early intervention efforts of recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) against nasopharyngeal cancer with radiation-induced oral mucositis.Methods: A total of 75 patients with nasopharyngeal cancer were randomly assigned to 3 groups: the prevention group (n = 25) used rhGM-CSF when radiation started one day, the treatment group (n = 25) and the control group (n = 25) used rhGM-CSF when oral mucositis occurred. Criteria of CTC was used to evaluate the duration of oral mucositis and degree of oral pain.Results: The prevention group had a longer duration of oral mucositis of oral mucositis when comparing with the treatment group and the control group (15.2±3.2), (12.1 ±2.7), (12.0±2.6) d (t = 3.725, P = 0.001; t = 3.939, P = 0.000). As compared with the control and experiment group, the degree of mucosal damage in the prevention group was significantly lower. II level and above oral mucositis were about 68 % (17/25), 92 % (23/25) and 100 % (25/25) respectively (P = 0.000). According to subgroup analysis, prophylactic rhGM-CSF in radiation-induced oral mucositis can better reduce the incidence of II level and above oral mucositis (P < 0.05), and treatment group can reduce the incidence of III level oral mucositis (P < 0.05).Conclusion: rhGM-CSF early intervention can better improve nasopharyngeal cancer with radiation-induced oral mucositis.